0000899243-15-001327.txt : 20150716
0000899243-15-001327.hdr.sgml : 20150716
20150716173551
ACCESSION NUMBER: 0000899243-15-001327
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150714
FILED AS OF DATE: 20150716
DATE AS OF CHANGE: 20150716
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMMUNOMEDICS INC
CENTRAL INDEX KEY: 0000722830
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 611009366
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 300 AMERICAN RD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
BUSINESS PHONE: 9736058200
MAIL ADDRESS:
STREET 1: 300 AMERICAN ROAD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GOLDENBERG DAVID M
CENTRAL INDEX KEY: 0001029578
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12104
FILM NUMBER: 15992191
MAIL ADDRESS:
STREET 1: UBS GLOBAL ASSET MANAGEMENT (US) INC.
STREET 2: 51 WEST 52ND STREET
CITY: NEW YORK
STATE: NY
ZIP: 10019
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-07-14
0
0000722830
IMMUNOMEDICS INC
IMMU
0001029578
GOLDENBERG DAVID M
C/O IMMUNOMEDICS, INC.
300 AMERICAN ROAD
MORRIS PLAINS
NJ
07950
1
1
0
0
CSO & Chairman of the BOD
Performance Rights
2015-07-14
4
A
0
1500000
0.00
A
2020-07-14
Common Stock, par value $0.01 per share
1500000
1500000
D
Each performance right represents a contingent right to receive one share of Immunomedics, Inc. common stock. The performance rights will vest (i) as to 500,000 shares (a) on or after the third anniversary of the grant date and (b) upon Immunomedics, Inc. common stock achieving a fair market value of $7.35 or higher based on the average closing price for the prior 30 consecutive trading days; (ii) as to 500,000 shares (a) on or after the third anniversary of the grant date and (b) upon Immunomedics, Inc. common stock achieving a fair market value of $11.00 or higher based on the average closing price for the prior 30 consecutive trading days; and (iii) as to 500,000 shares (a) on or after the third anniversary of the grant date and (b) upon Immunomedics, Inc. common stock achieving a fair market value of $15.00 or higher based on the average closing price for the prior 30 consecutive trading days.
/s/ David M. Goldenberg
2015-07-16